GENZYME CORP Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 128 rows in 2008. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2008-12-10: Reporting owner Amello Jason; Form 3; Security Genzyme NQ stock option (right to buy); Transaction Holding.
- 2008-12-10: Reporting owner Amello Jason; Form 3; Security Genzyme NQ Stock Option (right to buy); Transaction Holding.
- 2008-12-10: Reporting owner Amello Jason; Form 3; Security Genzyme NQ Stock Option (right to buy); Transaction Holding.
- 2008-12-10: Reporting owner Amello Jason; Form 3; Security Genzyme NQ stock option (right to buy); Transaction Holding.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2008-12-10 holding as of filing | Amello Jason Other (CorpContrllr,ChiefAccntOfficer) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $135.25 exercise price | 2008-12-10 | ||
| 2008-12-10 holding as of filing | Amello Jason Other (CorpContrllr,ChiefAccntOfficer) | 3 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | Holding | $46.24 exercise price | 2008-12-10 | ||
| 2008-12-10 holding as of filing | Amello Jason Other (CorpContrllr,ChiefAccntOfficer) | 3 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | Holding | $48.38 exercise price | 2008-12-10 | ||
| 2008-12-10 holding as of filing | Amello Jason Other (CorpContrllr,ChiefAccntOfficer) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $43.90 exercise price | 2008-12-10 | ||
| 2008-12-10 holding as of filing | Amello Jason Other (CorpContrllr,ChiefAccntOfficer) | 3 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | Holding | $62.98 exercise price | 2008-12-10 | ||
| 2008-12-10 holding as of filing | Amello Jason Other (CorpContrllr,ChiefAccntOfficer) | 3 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | Holding | $58.50 exercise price | 2008-12-10 | ||
| 2008-12-10 holding as of filing | Amello Jason Other (CorpContrllr,ChiefAccntOfficer) | 3 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | Holding | $62.16 exercise price | 2008-12-10 | ||
| 2008-12-10 holding as of filing | Amello Jason Other (CorpContrllr,ChiefAccntOfficer) | 3 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | Holding | $68.48 exercise price | 2008-12-10 | ||
| 2008-12-08 | SMITH ALAN E Officer (Sr VP,Chief Scientific Officer) | 4 | Genzyme NQ stock option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −55,521 0 owned after | $29.44 exercise price | 2008-12-10 | |
| 2008-09-23 | MOSCICKI RICHARD A Officer (Sr VP,Chief Medical Officer) | 4 | Genzyme NQ stock option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −23,201 0 owned after | $29.44 exercise price | 2008-09-25 | |
| 2008-09-23 | MOSCICKI RICHARD A Officer (Sr VP,Chief Medical Officer) | 4 | Genzyme NQ stock option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −13,434 18,318 owned after | $26.50 exercise price | 2008-09-25 | |
| 2008-08-15 | Meeker David P Officer (President LSD Therapeutics) | 4 | Genzyme ISO stock option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −15,988 0 owned after | $20.59 exercise price | 2008-08-18 | |
| 2008-08-15 | Meeker David P Officer (President LSD Therapeutics) | 4 | Genzyme NQ stock option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,802 0 owned after | $20.59 exercise price | 2008-08-18 | |
| 2008-08-14 | SMITH ALAN E Officer (Senior Vice President) | 4 | Genzyme NQ stock option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −15,000 66,300 owned after | $32.52 exercise price | 2008-08-15 | |
| 2008-08-14 | Bamforth Mark R Officer (Sr.VP, Corp. Operations & Phar) | 4 | Genzyme NQ stock option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −32 0 owned after | $41.50 exercise price | 2008-08-15 | |
| 2008-08-14 | Bamforth Mark R Officer (Sr.VP, Corp. Operations & Phar) | 4 | Genzyme NQ stock option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −19,200 0 owned after | $43.90 exercise price | 2008-08-15 | |
| 2008-08-12 | WYZGA MICHAEL S Officer (Executive VP and CFO) | 4 | Genzyme ISO stock option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −13,679 0 owned after | $32.52 exercise price | 2008-08-13 | |
| 2008-08-12 | WYZGA MICHAEL S Officer (Executive VP and CFO) | 4 | Genzyme NQ stock option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −15,545 0 owned after | $32.52 exercise price | 2008-08-13 | |
| 2008-08-12 | WYZGA MICHAEL S Officer (Executive VP and CFO) | 4 | Genzyme NQ stock option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −166 0 owned after | $41.50 exercise price | 2008-08-13 | |
| 2008-08-07 | DesRosier Thomas Officer (Sr VP General Counsel) | 4 | Genzyme NQ stock option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,725 0 owned after | $32.52 exercise price | 2008-08-08 | |
| 2008-08-06 | Bamforth Mark R Officer (Sr.VP, Corp. Operations & Phar) | 4 | Genzyme NQ stock option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −6,445 0 owned after | $32.52 exercise price | 2008-08-07 | |
| 2008-08-05 | SMITH ALAN E Officer (Senior Vice President) | 4 | Genzyme NQ stock option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −27,761 55,521 owned after | $29.44 exercise price | 2008-08-06 | |
| 2008-07-15 | SMITH ALAN E Officer (Senior Vice President) | 4/A | Genzyme NQ stock option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −18,455 16,149 owned after | $26.50 | 2008-08-04 | |
| 2008-07-15 | Bamforth Mark R Officer (Sr.VP, Corp. Operations & Phar) | 4/A | Genzyme NQ stock option (right to buy) Derivative · Direct | J Other acquisition or disposition (describe transaction) | +6,445 6,445 owned after | $32.52 | 2008-08-04 | |
| 2008-07-15 | SMITH ALAN E Officer (Senior Vice President) | 4 | Genzyme NQ stock option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | +18,455 53,059 owned after | $26.50 | 2008-07-17 | |
| 2008-07-15 | Bamforth Mark R Officer (Sr.VP, Corp. Operations & Phar) | 4 | Genzyme NQ stock option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | +6,445 12,890 owned after | $32.52 | 2008-07-17 | |
| 2008-07-08 | COLLIER EARL M JR Officer (Executive Vice President) | 4 | Genzyme NQ stock option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −16,200 0 owned after | $43.90 exercise price | 2008-07-10 | |
| 2008-06-25 | MOSCICKI RICHARD A Officer (Senior Vice President) | 4 | Genzyme NQ stock option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −36,635 23,201 owned after | $29.44 exercise price | 2008-06-27 | |
| 2008-05-23 holding as of filing | Meeker David P Officer (President LSD Therapeutics) | 3 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | Holding | $62.98 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | Meeker David P Officer (President LSD Therapeutics) | 3 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | Holding | $58.50 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | Meeker David P Officer (President LSD Therapeutics) | 3 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | Holding | $62.16 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | Meeker David P Officer (President LSD Therapeutics) | 3 | Genzyme ISO stock option (right to buy) Derivative · Direct | Holding | $20.59 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | Meeker David P Officer (President LSD Therapeutics) | 3 | Genzyme ISO Stock Option (right to buy) Derivative · Direct | Holding | $58.50 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | Meeker David P Officer (President LSD Therapeutics) | 3 | Genzyme ISO stock option (right to buy) Derivative · Direct | Holding | $62.16 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | Meeker David P Officer (President LSD Therapeutics) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $20.59 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | Meeker David P Officer (President LSD Therapeutics) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $223.18 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | Meeker David P Officer (President LSD Therapeutics) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $26.50 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | Meeker David P Officer (President LSD Therapeutics) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $135.25 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | Meeker David P Officer (President LSD Therapeutics) | 3 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | Holding | $50.02 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | Meeker David P Officer (President LSD Therapeutics) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $53.47 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | Meeker David P Officer (President LSD Therapeutics) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $32.52 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | Meeker David P Officer (President LSD Therapeutics) | 3 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | Holding | $27.46 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | Meeker David P Officer (President LSD Therapeutics) | 3 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | Holding | $30.57 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | Meeker David P Officer (President LSD Therapeutics) | 3 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | Holding | $46.24 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | Meeker David P Officer (President LSD Therapeutics) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $43.90 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | GERAGHTY JAMES A Officer (Senior Vice President) | 3 | Genzyme ISO stock option (right to buy) Derivative · Direct | Holding | $32.52 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | GERAGHTY JAMES A Officer (Senior Vice President) | 3 | Genzyme ISO stock option (right to buy) Derivative · Direct | Holding | $62.16 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | GERAGHTY JAMES A Officer (Senior Vice President) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $124.69 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | GERAGHTY JAMES A Officer (Senior Vice President) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $392.13 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | GERAGHTY JAMES A Officer (Senior Vice President) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $95.76 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | GERAGHTY JAMES A Officer (Senior Vice President) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $467.56 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | GERAGHTY JAMES A Officer (Senior Vice President) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $223.18 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | GERAGHTY JAMES A Officer (Senior Vice President) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $226.75 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | GERAGHTY JAMES A Officer (Senior Vice President) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $135.25 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | GERAGHTY JAMES A Officer (Senior Vice President) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $53.47 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | GERAGHTY JAMES A Officer (Senior Vice President) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $126.59 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | GERAGHTY JAMES A Officer (Senior Vice President) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $274.31 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | GERAGHTY JAMES A Officer (Senior Vice President) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $32.52 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | GERAGHTY JAMES A Officer (Senior Vice President) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $85.74 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | GERAGHTY JAMES A Officer (Senior Vice President) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $41.50 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | GERAGHTY JAMES A Officer (Senior Vice President) | 3 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | Holding | $46.24 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | GERAGHTY JAMES A Officer (Senior Vice President) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $43.90 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | GERAGHTY JAMES A Officer (Senior Vice President) | 3 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | Holding | $62.98 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | GERAGHTY JAMES A Officer (Senior Vice President) | 3 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | Holding | $58.50 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | GERAGHTY JAMES A Officer (Senior Vice President) | 3 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | Holding | $62.16 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | DesRosier Thomas Officer (Sr VP General Counsel) | 3 | Genzyme ISO stock option (right to buy) Derivative · Direct | Holding | $32.52 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | DesRosier Thomas Officer (Sr VP General Counsel) | 3 | Genzyme ISO stock option (right to buy) Derivative · Direct | Holding | $62.16 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | DesRosier Thomas Officer (Sr VP General Counsel) | 3 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | Holding | $184.79 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | DesRosier Thomas Officer (Sr VP General Counsel) | 3 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | Holding | $102.42 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | DesRosier Thomas Officer (Sr VP General Counsel) | 3 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | Holding | $369.59 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | DesRosier Thomas Officer (Sr VP General Counsel) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $223.18 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | DesRosier Thomas Officer (Sr VP General Counsel) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $226.75 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | DesRosier Thomas Officer (Sr VP General Counsel) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $135.25 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | DesRosier Thomas Officer (Sr VP General Counsel) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $126.59 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | DesRosier Thomas Officer (Sr VP General Counsel) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $274.31 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | DesRosier Thomas Officer (Sr VP General Counsel) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $32.52 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | DesRosier Thomas Officer (Sr VP General Counsel) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $85.74 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | DesRosier Thomas Officer (Sr VP General Counsel) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $41.50 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | DesRosier Thomas Officer (Sr VP General Counsel) | 3 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | Holding | $46.24 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | DesRosier Thomas Officer (Sr VP General Counsel) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $43.90 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | DesRosier Thomas Officer (Sr VP General Counsel) | 3 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | Holding | $62.98 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | DesRosier Thomas Officer (Sr VP General Counsel) | 3 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | Holding | $58.50 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | DesRosier Thomas Officer (Sr VP General Counsel) | 3 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | Holding | $62.16 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | Bamforth Mark R Officer (Sr.VP, Corp. Operations & Phar) | 3 | Genzyme ISO stock option (right to buy) Derivative · Direct | Holding | $62.16 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | Bamforth Mark R Officer (Sr.VP, Corp. Operations & Phar) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $53.47 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | Bamforth Mark R Officer (Sr.VP, Corp. Operations & Phar) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $126.59 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | Bamforth Mark R Officer (Sr.VP, Corp. Operations & Phar) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $274.31 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | Bamforth Mark R Officer (Sr.VP, Corp. Operations & Phar) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $32.52 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | Bamforth Mark R Officer (Sr.VP, Corp. Operations & Phar) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $85.74 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | Bamforth Mark R Officer (Sr.VP, Corp. Operations & Phar) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $41.50 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | Bamforth Mark R Officer (Sr.VP, Corp. Operations & Phar) | 3 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | Holding | $46.24 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | Bamforth Mark R Officer (Sr.VP, Corp. Operations & Phar) | 3 | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $43.90 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | Bamforth Mark R Officer (Sr.VP, Corp. Operations & Phar) | 3 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | Holding | $62.98 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | Bamforth Mark R Officer (Sr.VP, Corp. Operations & Phar) | 3 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | Holding | $58.50 exercise price | 2008-05-23 | ||
| 2008-05-23 holding as of filing | Bamforth Mark R Officer (Sr.VP, Corp. Operations & Phar) | 3 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | Holding | $62.16 exercise price | 2008-05-23 | ||
| 2008-05-22 | WYZGA MICHAEL S Officer (Executive VP and CFO) | 4 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +45,000 45,000 owned after | $68.48 exercise price | 2008-05-27 | |
| 2008-05-22 | WIRTH PETER Officer (Executive Vice President) | 4 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +45,000 45,000 owned after | $68.48 exercise price | 2008-05-27 | |
| 2008-05-22 | TERMEER HENRI A Director, Officer (Chmn, President and CEO) | 4 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +200,000 200,000 owned after | $68.48 exercise price | 2008-05-27 | |
| 2008-05-22 | SMITH SANDFORD D Officer (Executive Vice President) | 4 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +45,000 45,000 owned after | $68.48 exercise price | 2008-05-27 | |
| 2008-05-22 | SMITH ALAN E Officer (Senior Vice President) | 4 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +24,250 24,250 owned after | $68.48 exercise price | 2008-05-27 |